Drug metabolism in the 1960s
At the time the Liver Unit was established in 1966, interest in the study of drug metabolism was growing, stimulated largely by the pharmaceutical industry, and the legislative requirements imposed upon it. It represented a remarkable change from the situation a few years previously when'. . . the study ofthe metabolism of foreign compounds was not a popular one; biochemists considered it rather a waste of time and effort, both of which could be better expended on looking at naturally occurring substances. Pharmacologists also had little interest in the subject and regarded it as unrelated to their immediate problems. Toxicology was in a primitive state of development and still largely concerned with cataloguing and describing the effects of various poisons'.' By the 1960s, however, centres in Britain, Europe, and the United States had begun to characterise the drug metabolising enzymes and their responses to repeated drug ingestion. In 1966, novel discoveries emphasised: (i) the existence of more than one form of cytochrome P-450,2 the basic function3 and characterisation45 of which had been defined only in the previous three years; (ii) the clinical implications ofenzyme induction to drug therapy, as illustrated by three case reports, one describing fatal haemorrhage after withdrawal of the enzyme inducing sedative chloral hydrate in a patient on anticoagulants,' and two showing relief of paediatric jaundice with phenobarbitone; 8 (iii) the hepatotoxicity ofenvironmental toxins, after the outbreak of Epping jaundice resulting from contamination of flour with 4,4-diamino-diphenylmethane. 9 The limited understanding of the mechanisms of hepatotoxic drug reactions at that time can It was well known that the capacity of an individual to acetylate drugs is genetically determined,38 with the population divided into rapid and slow acetylators. Research from St Mary's Hospital Medical School, London showed that a similar polymorphism applied to a pathway of oxidative metabolism, the hydroxylation of debrisoquine.39 This provided a potential for determining susceptibility to liver damage from some therapeutic agents as a result of differences in the rates at which individuals metabolised a drug through 'safe' or potentially hepatotoxic pathways. It was some years, however, before well characterised examples emerged. Thus, the half life of the antianginal drug, perhexiline maleate, is much prolonged in poor hydroxylators of debrisoquine& and this seems to be associated with drug accumulation and microvesicular phospholipidosis.4' Different considerations apply to liver damage from the antituberculous drug isoniazid. Slow acetylators of the drug metabolise more through oxidation which can produce a reactive hydrazine derivative, and there is a higher incidence of liver damage amongst individuals with the slow acetylator phenotype.42 Genetic variations in oxidative metabolism are also likely to be important, as are responses to environmental influences. For example, concomitant exposure to rifampicin induces the metabolism of hydrazine and increases the risk of hepatotoxicity. 43 Another factor determining susceptibility to some types of hepatotoxic drug reaction is the capacity to mount an immune response against drug altered liver components. A series of investigations carried out in the Liver Unit identified an antibody directed against a hepatocyte surface antigen altered by a halothane metabolite.' The altered antigenic determinant probably results from oxidative halothane metabolism45 which generates trifluroacetylated proteins"" (Fig 2) .
It is likely that all individuals exposed to the drug generate altered hepatocyte membrane determinants,49 but only a small minority mount an immunological reaction against them.50 The fact that many patients with severe halothane hepatitis have circulating antibodies directed against other organs in the body5' strongly suggests an underlying, genetically determined defect in immune regulation.52 In contrast, some patients with hepatitis from the drug have no evidence of immune involvement, and liver damage in these cases is probably the result ofoverproduction of a hepatotoxic derivative produced by reductive halothane metabolism. Preferential stimulation of this pathway in experimental animals produces dose related hepatotoxicity53 (Fig 2) .
Subsequently, the methods validated with halothane have been used to show a possible immune basis for drug hepatotoxicity from a-methyldopa54 tienilic acid55 and ethanol.56 In addition to expressing an antibody reacting with tienilic acid derived neoantigens, more than 50% of patients with tienilic acid hepatitis produce an antibody (a-LKM2) directed against a cytochrome P-450 II isoenzyme (P-450 8; P-450 MP). Both this and the analogous LKM1 antibody (a-P-450 IID) have been associated with however, such as paracetamol hepatotoxicity, seems assured. Here, and for many hepatotoxic drugs, characterisation of qualitative aspects of the covalent binding process is of obvious relevance. Obtaining evidence for the intracellular sites involved, the enzymes and cellular functions affected and the possibility of reversing such interactions is of high priority. This approach may be relevant to those drugs which are toxic directly through reactive metabolites and those invoking immune responses. For the latter, one emphasis in the immediate future must be to identify how drug related antigens are translocated to the cell surface, complementing investigations into the role of endogenous molecules such as cytochrome P-450 in autoimmune disease. Drug metabolists and immunologists together must then unravel the mechanisms underlying idiosyncrasy in immune mediated drug reactions. This may not only refine preclinical screening for drug toxicity, but will also lead to new treatment regimens to improve the safety of existing drugs.
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